Comparing all-cause, cardiovascular and infection-related mortality of deciles of serum ferritin.

<p>Cut-off levels: 21, 41, 67, 98, 133, 177, 232, 321, and 496 ng/mL. CV, cardiovascular.</p

Baseline characteristics of patients undergoing dialysis.

<p>Means±SD or medians and interquartile range (IQR)</p><p>Abbreviations: HD, hemodialysis; PD, peritoneal dialysis; TIBC, total iron binding capacity; TSAT, transferrin saturation; BUN, blood urea nitrogen; CRP, C-reactive protein; PTH, parathyroid hormone.</p><p>Baseline characteristics of patients undergoing dialysis.</p

Associations between serum magnesium levels and Proton Pump inhibitor use as determined by regression analyses.

<p>Reference category is the patients on no acid suppressive medications. β-coefficients ± s.e’s and <i>P</i> values are provide for each variable. Model I includes age, dialysis vintage and sex. Model II includes all variables in Model I and the addition of Diabetes mellitus, Kt/V, systolic blood pressure, albumin, potassium, C-reactive protein, sodium, blood urea nitrogen, parathyroid hormone, phosphorus, calcium, hemoglobin, furosemide, antiplatelet drug, vitamin K antagonist, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, phosphate binder, vitamin D receptor antagonist, atrial fibrillation, gastric hemorrhage, cerebral infarction, and ischemic heart disease. Conversion factors for units: serum magnesium in mg/dL to mol/L, *0.4114.</p><p>Associations between serum magnesium levels and Proton Pump inhibitor use as determined by regression analyses.</p

Patient characteristics.

<p><i>P</i> values reflect group across differences. Abbreviations: H2,histamine 2; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker. Conversion factors for units: serum creatinine in mg/dL to mol/L, *88.4; blood urea nitrogen in mg/dL to mmol/L,*0.357; Calcium in mg/dL to mmol/L,*0.2495; Phosphorus in mg/dL to mmol/L, *0.3229.</p><p>Patient characteristics.</p

Effect of diuretic use and hemodialysis vintage on association between acid suppressive therapy and serum magnesium.

<p>Abbreviation: H2, histamine-2. Reference category is patients on no acid-suppressive medications. β-coefficients ± s.e’s and <i>P</i> values are provided for each variable. Adjusted models includes age, dialysis vintage, sex, Diabetes mellitus, Kt/V, systolic blood pressure, albumin, potassium, C-reactive protein, sodium, blood urea nitrogen, parathyroid hormone, phosphorus, calcium, hemoglobin, furosemide, antiplatelet drug, vitamin K antagonist, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, phosphate binder, vitamin D receptor antagonist, atrial fibrillation, gastric hemorrhage, cerebral infarction, and ischemic heart disease.</p><p>Effect of diuretic use and hemodialysis vintage on association between acid suppressive therapy and serum magnesium.</p

Logistic analysis between Proton Pump inhibitor use and hypomagnesemia.

<p>Hypomagnesemia is defined as ≤ 2.0 mg/dL (0.82mmol/L). Adjusted models includes age, dialysis vintage, sex, Diabetes mellitus, Kt/V, systolic blood pressure, albumin, potassium, C-reactive protein, sodium, blood urea nitrogen, parathyroid hormone, phosphorus, calcium, hemoglobin, furosemide, antiplatelet drug, vitamin K antagonist, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker, phosphate binder, vitamin D receptor antagonist, atrial fibrillation, gastric hemorrhage, cerebral infarction, and ischemic heart disease.</p><p>Logistic analysis between Proton Pump inhibitor use and hypomagnesemia.</p

Comparison of all-cause, cardiovascular and infection-related mortality rates of deciles of hemoglobin levels.

<p>Cut-off levels: 8.8, 9.4, 9.8, 10.1, 10.4, 10.7, 11.0, 11.3, and 11.9 g/dL. CV, cardiovascular.</p

Comparison of all-cause, cardiovascular and infection-related mortality of deciles of transferrin saturation.

<p>Cut-off levels: 13.1%, 17.1%, 20.2%, 23.0%, 25.7%, 28.6%, 32.1%, 36.7% and 44.8%. CV, cardiovascular; TSAT, transferrin saturation.</p

Multiple ordered logistic regression model to see the interaction between Fok<i>I</i> genotypes and 25OHD/1,25OHD levels on eGFR stage adjusted with 7 possible confounders^*.

*<p>All variables in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0051171#pone-0051171-t002" target="_blank">table 2</a> as well as confounders disease duration; use of ACEI/ARB; use of statin; serum Ca, P, and iPTH levels; and calendar month were simultaneously computed with ordered logistic regression model.</p

Histogram of circulating 25OHD levels (A) and 1, 25OHD levels (B) in patients with type 2 diabetes and with CKD stage 1∼5.

<p>Blood sampling was performed at entry; thus disease duration differed among patients. Serum 25OHD and 1,25OHD were measured by radioimmunoassay.</p